C4 Therapeutics presents new data for CFT1946 at AACR

C4 Therapeutics presented a poster today at the American Association for Cancer Research AACR Annual Meeting 2024 highlighting new preclinical data for CFT1946 across multiple models of BRAF V600X mutant colorectal cancer CRC and non-small cell lung cancer NSCLC , additional BRAF inhibitor BRAFi -resistant melanoma models, and an intracranial model of BRAF V600E metastatic melanoma. CFT1946 is an orally bioavailable BiDAC degrader that selectively degrades the BRAF V600X mutant protein and prevents RAF dimer-mediated resistance. While currently approved BRAF inhibitors are also selective for BRAF V600X mutant proteins, their activity is limited by primary or acquired resistance often mediated by mechanisms that promote RAF dimerization. Further, in a significant number of patients with BRAF V600X melanoma and NSCLC, the disease metastasizes to the brain. BRAF inhibitors have limited brain penetration, while CFT1946 demonstrates CNS activity in preclinical models.